Skip to main content
. 2024 Jul 16;35(3):102267. doi: 10.1016/j.omtn.2024.102267

Figure 1.

Figure 1

Design and testing of PD-1 peptides

(A) CLUSTAL Omega24 multiple sequence alignment of human PD1 (NP_005009) and mouse PD1 (NP_032824). The binding sites of nivolumab and pembrolizumab are shown. Corresponding mouse peptide sequences are highlighted: PD1N (purple), PD1P (blue). (B) Inhibition of PD-1 ELISA by synthetic peptides. Mean ± standard deviation, ∗∗∗∗p < 0.0001.